VENCLEXTA (Abbvie Pty Ltd)
Product name
VENCLEXTA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
149 (255 working days)
Active ingredients
venetoclax
Registration type
EOI
Indication
VENCLEXTA in combination with ibrutinib is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL)